These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19384840

  • 1. Antiproteinuric effect of olmesartan in patients with IgA nephropathy.
    Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, Utsunomiya Y, Yasuda T, Toyoda M, Tsuge T, Kaneko K.
    J Nephrol; 2009; 22(2):224-31. PubMed ID: 19384840
    [Abstract] [Full Text] [Related]

  • 2. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
    Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
    [Abstract] [Full Text] [Related]

  • 3. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 4. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 5. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [Abstract] [Full Text] [Related]

  • 6. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 May; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 7. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.
    Smolensky MH, Hermida RC, Portaluppi F.
    Chronobiol Int; 2007 Sep; 24(1):171-81. PubMed ID: 17364587
    [Abstract] [Full Text] [Related]

  • 9. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 10. The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
    Goyache-Goñi B, Aranda-Lara P, Reyes-Engels A, Frutos-Sanz MA, Hernández-Marrero D.
    Nefrologia; 2013 Nov 13; 33(6):771-8. PubMed ID: 24241364
    [Abstract] [Full Text] [Related]

  • 11. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.
    Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK.
    Am J Kidney Dis; 2008 May 13; 51(5):724-31. PubMed ID: 18436082
    [Abstract] [Full Text] [Related]

  • 12. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005 May 13; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 13. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function.
    Palla R, Panichi V, Finato V, Parrini M, Andreini B, Bianchi AM, Giovannini L, Migliori M, Bertelli AA.
    Int J Clin Pharmacol Res; 1994 May 13; 14(1):35-43. PubMed ID: 7927959
    [Abstract] [Full Text] [Related]

  • 14. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S, Ito M, Izuhara Y, Van Ypersele De Strihou C, Miyata T.
    Nephrology (Carlton); 2008 Dec 13; 13(6):517-21. PubMed ID: 18363646
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
    Hypertens Res; 2009 Apr 13; 32(4):270-5. PubMed ID: 19262495
    [Abstract] [Full Text] [Related]

  • 16. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL, Januszewicz A.
    J Hypertens; 2006 Feb 13; 24(2):403-8. PubMed ID: 16508590
    [Abstract] [Full Text] [Related]

  • 17. Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases.
    Park HC, Choi HY, Kim BS, An HR, Lee JS, Ha SK, Han DS.
    Biomed Pharmacother; 2009 Nov 13; 63(9):672-8. PubMed ID: 19278811
    [Abstract] [Full Text] [Related]

  • 18. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov 13; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 19. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
    Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H.
    J Am Coll Cardiol; 2007 Sep 18; 50(12):1144-9. PubMed ID: 17868805
    [Abstract] [Full Text] [Related]

  • 20. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ, Song JH, Suh JH, Lee SW, Kim GA.
    Yonsei Med J; 2003 Jun 30; 44(3):463-72. PubMed ID: 12833584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.